Zepzelca combo becomes first approved maintenance treatment for extensive-stage small cell lung cancer, a historically difficult-to-treat disease.
Shares surge over 26% after the company announces its largest US order in three years for 50,000 mining machines.
The all-cash deal allows Occidental to pay down significant debt and sharpen its focus on core oil and gas exploration.
The approval marks a new standard for first-line maintenance treatment in extensive-stage small cell lung cancer, a historically challenging disease.
Investors signal concern that the expiring federal EV tax credit created a 'pull-forward' of demand, raising questions about future growth.
Permanent J-Code from CMS aims to streamline reimbursement and broaden patient access for its graft-versus-host disease treatment.
Analyst confidence swells following positive FDA alignment on the company's pivotal gene therapy trial for Rett Syndrome.
Stock soars as government backing for domestic lithium production and positive sector sentiment fuel investor optimism.